<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00859755</url>
  </required_header>
  <id_info>
    <org_study_id>ARRAY-403-101</org_study_id>
    <nct_id>NCT00859755</nct_id>
  </id_info>
  <brief_title>A Safety Study of ARRY-403 in Patients With Type 2 Diabetes</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Array BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Array BioPharma</source>
  <brief_summary>
    <textblock>
      This is a Phase 1 study, involving a 1-day dosing period, designed to test the safety of
      investigational study drug ARRY-403 in patients with Type 2 diabetes. Approximately 36
      patients from the US will be enrolled in this study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Characterize the safety profile of the study drug in terms of adverse events, clinical laboratory tests, vital signs and electrocardiograms.</measure>
    <time_frame>Duration of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize the pharmacokinetics (PK) of the study drug and metabolites in terms of plasma concentrations.</measure>
    <time_frame>Day 1, Day 2</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize the pharmacodynamic (PD) activity of the study drug on biomarkers.</measure>
    <time_frame>Day 1, Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the ability of the study drug to improve glucose tolerance as determined by blood glucose monitoring during a standardized meal challenge.</measure>
    <time_frame>Day 1, Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the excretion of the study drug and metabolites in urine following dosing.</measure>
    <time_frame>Day 1, Day 2</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>ARRY-403</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARRY-403, glucokinase activator; oral</intervention_name>
    <description>single dose, escalating</description>
    <arm_group_label>ARRY-403</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo; oral</intervention_name>
    <description>matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Male or female with willingness and ability to use protocol-specified methods of
             contraception, except females of nonchildbearing potential.

          -  Diagnosis of Type 2 diabetes less than 5 years prior to study start.

          -  HbA1c ≥ 6.5% and ≤ 10%.

          -  BMI ≥ 25 and ≤ 40.0 kg/m2.

          -  Additional criteria exist.

        Key Exclusion Criteria:

          -  Recent history (i.e., less than 6 months) or concomitant/ongoing clinically
             significant hematologic, renal, pulmonary, gastrointestinal, hepatic, psychiatric,
             neurologic, dermatologic, or allergic disease (including drug allergies that are
             clinically significant and not remote, but excluding untreated, asymptomatic, seasonal
             allergies at the time of dosing).

          -  Significant cardiac disease, myocardial infarction within 6 months of study start,
             unstable angina, congestive heart failure, known arrhythmias of ventricular etiology,
             unexplained syncope or syncope/seizures related to arrhythmia.

          -  History of gastric surgery, vagotomy, bowel resection, or any surgical procedure that
             might interfere with gastrointestinal motility, pH, or absorption.

          -  Active infectious diseases including hepatitis B, hepatitis C, or human
             immunodeficiency virus (HIV). Past history and inactive hepatitis B and C, as
             confirmed by serological testing, are allowed.

          -  A positive test for drugs or alcohol.

          -  Women who are pregnant or breastfeeding.

          -  Donation or loss of ≥ 550 mL of blood (including plasmapheresis) or receipt of a
             transfusion of any blood product within 8 weeks prior to first dose of study drug.

          -  Additional criteria exist.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Profil Institute for Clinical Research, Inc.</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2009</study_first_submitted>
  <study_first_submitted_qc>March 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2009</study_first_posted>
  <last_update_submitted>August 29, 2012</last_update_submitted>
  <last_update_submitted_qc>August 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

